← back to search

Lesley Burgess

Clinical Trial Investigators ·
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Lipoproteins and Cardiovascular Health, Art Education and Development, Pericarditis and Cardiac Tamponade, and Pleural and Pulmonary Diseases.
h-index
34
citations
11,437
works
126
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial
The Lancet 2026cited by 5position: middledoi
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial
European Heart Journal 2024cited by 23position: middledoi
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
Annals of Internal Medicine 2022cited by 71position: middledoi
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.
2022cited by 50position: contributordoi
Evinacumab in Patients with Refractory Hypercholesterolemia
New England Journal of Medicine 2020cited by 291position: middledoi
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
New England Journal of Medicine 2014cited by 709position: middledoi
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Circulation 2014cited by 664position: middledoi
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
European Heart Journal 2014cited by 95position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Matteo Bassetti · Istituto Nazionale di Fisica Nucleare, Sezione di Genova2 papers (2022–2022)Norio Ohmagari · National Center for Global Health and Medicine2 papers (2022–2022)Timo Wolf · Goethe University Frankfurt2 papers (2022–2022)Sanjay Bhagani · Royal Free London NHS Foundation Trust2 papers (2022–2022)— · 1 papers (2020–2020)Carisa De Anda · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2022–2022)Kate Tsirtsonis · Amgen (United States)1 papers (2014–2014)Robert Pordy · Regeneron (United States)1 papers (2020–2020)Michael A. Bolognese · Amgen (United States)1 papers (2014–2014)— · 1 papers (2014–2014)Maria Laura Monsalvo · Amgen (United States)1 papers (2014–2014)Christie M. Ballantyne · New York University1 papers (2014–2014)Amy Puenpatom · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2022–2022)Michael Lillestol · Çevre, Şehircilik ve İklim Değişikliği Bakanlığı1 papers (2014–2014)Robert S. Rosenson · Montreal Heart Institute1 papers (2020–2020)— · 1 papers (2020–2020)Nagwa Khilla · Regeneron (United States)1 papers (2020–2020)Robert C. Scott · Japan Real Estate Institute1 papers (2014–2014)Angela Williams‐Diaz · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2022–2022)Christoph Ebenbichler · University Hospital Innsbruck1 papers (2020–2020)